2013-04-26 07:32:02 -
MorphoSys AG /
MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in B-cell Acute
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX) announced today that it
has dosed the first patient in a Phase 2 clinical trial of MOR208 in B-cell
acute lymphoblastic leukemia (B-ALL). MOR208 is a potent monoclonal Fc optimized
anti-CD19 antibody to which MorphoSys gained worldwide access via an exclusive
license and collaboration agreement with Xencor in 2010.
The US-based study is an open-label, multicenter, single-arm clinical trial
designed to assess the efficacy of MOR208 in patients suffering from relapsed
refractory B-ALL. Secondary outcome measures include response duration, safety
and pharmacokinetics of MOR208. In total, 30 patients are planned to be
enrolled. More information on the trial can be found by searching for MOR208 at
"Due to its high expression levels on non-Hodgkin's lymphomas and B-cell
leukemias CD19 represents a particularly attractive immunotherapy target for
hematological cancers," commented Dr. Arndt Schottelius, Chief Development
Officer of MorphoSys AG. "What is unique about MOR208 is that the antibody
comprises only a very minor change to the Fc part of the molecule leading to
significantly increased potency."
MOR208 has shown in a Phase 1/2a trial encouraging signs of preliminary anti-
tumor activity and an acceptable safety and tolerability profile in patients
with high-risk, heavily pretreated chronic lymphocytic leukemia (CLL) or small
lymphocytic lymphoma (SLL). In addition to the Phase 2 trial in B-ALL MorphoSys
is about to start a second Phase 2 trial in Non-Hodgkin's Lymphoma (NHL).
B-cell malignancies, such as B-ALL, NHL and CLL affect more than one hundred and
fifty thousand patients in the seven major markets each year. The target
molecule CD19 is expressed more broadly and earlier in B-cell development than
CD20, the target of the marketed cancer drug Rituxan(®). Therefore targeting
CD19 could potentially allow for an even broader therapeutic use of MOR208 than
marketed anti-CD20 antibodies.
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 70 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit www.morphosys.com
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®),
Ylanthia(®) and 100 billion high potentials(®) are registered trademarks of
Slonomics(®) is a registered trademark of Sloning BioTechnology GmbH, a
subsidiary of MorphoSys AG.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies. The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties. Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated.
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122
Associate Director Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332
Media Release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via Thomson Reuters ONE